Skip to main content

Compare Stocks

Date Range: 

 Johnson & JohnsonRocheAbbott LaboratoriesPfizerNovartis
SymbolNYSE:JNJOTCMKTS:RHHBYNYSE:ABTNYSE:PFENYSE:NVS
Price Information
Current Price$170.22$42.13$118.31$40.02$88.96
52 Week RangeBuyHoldBuyHoldHold
MarketRank™
Overall Score2.31.42.22.12.0
Analysis Score1.40.01.42.13.2
Community Score2.52.42.82.92.3
Dividend Score4.22.53.32.52.5
Ownership Score1.70.01.71.70.0
Earnings & Valuation Score1.91.91.91.31.9
Analyst Ratings
Consensus RecommendationBuyHoldBuyHoldHold
Consensus Price Target$185.70N/A$125.81$39.94$108.50
% Upside from Price Target9.09% upsideN/A6.34% upside-0.21% downside21.96% upside
Trade Information
Market Cap$448.26 billion$288.53 billion$210.22 billion$223.22 billion$203.60 billion
Beta0.70.350.830.70.59
Average Volume8,041,5751,868,9555,185,95132,200,0391,970,152
Sales & Book Value
Annual Revenue$82.06 billion$61.87 billion$31.90 billion$51.75 billion$47.50 billion
Price / Sales5.464.666.594.314.29
Cashflow$12.42 per share$3.06 per share$5.30 per share$4.46 per share$7.53 per share
Price / Cash13.7113.7722.318.9711.82
Book Value$22.60 per share$5.27 per share$17.70 per share$11.46 per share$24.53 per share
Price / Book7.537.996.683.493.63
Profitability
Net Income$15.12 billion$13.58 billion$3.69 billion$16.27 billion$11.73 billion
EPS$8.68$2.54$3.24$2.95$5.24
Trailing P/E Ratio26.7616.5962.6025.8228.79
Forward P/E Ratio19.1514.8927.0113.0813.64
P/E Growth3.063.692.062.791.76
Net Margins21.01%N/A10.50%17.85%14.71%
Return on Equity (ROE)34.64%N/A18.19%24.88%24.39%
Return on Assets (ROA)13.40%N/A8.29%9.32%10.59%
Dividend
Annual Payout$4.04$0.77$1.80$1.56$2.08
Dividend Yield2.37%1.83%1.52%3.90%2.34%
Three-Year Dividend Growth19.88%N/A35.85%-10.94%13.60%
Payout Ratio46.54%30.31%55.56%52.88%39.69%
Years of Consecutive Dividend Growth59 YearsN/A49 Years1 Years1 Years
Debt
Debt-to-Equity Ratio0.51%0.36%0.58%0.76%0.49%
Current Ratio1.48%1.23%1.70%1.40%0.91%
Quick Ratio1.24%0.93%1.19%1.13%0.69%
Ownership Information
Institutional Ownership Percentage67.25%0.32%72.58%67.36%9.86%
Insider Ownership Percentage0.27%N/A1.70%0.08%0.01%
Miscellaneous
Employees134,500101,465109,00078,500105,794
Shares Outstanding2.63 billion6.85 billion1.78 billion5.58 billion2.29 billion
Next Earnings Date7/15/2021 (Estimated)N/A7/15/2021 (Estimated)7/27/2021 (Estimated)7/20/2021 (Estimated)
OptionableOptionableNot OptionableOptionableOptionableOptionable
SourceHeadline
Novartis’s Piqray wins nod for breast cancer patients with gene-mutation - Korea Biomedical ReviewNovartis’s Piqray wins nod for breast cancer patients with gene-mutation - Korea Biomedical Review
koreabiomed.com - May 14 at 2:10 AM
Womens Health Beating Market By Excellent Revenue Growth: Novartis, Pfizer, Novo Nordisk – The Shotcaller - The ShotcallerWomen's Health Beating Market By Excellent Revenue Growth: Novartis, Pfizer, Novo Nordisk – The Shotcaller - The Shotcaller
theshotcaller.net - May 14 at 2:10 AM
Novartis taps Ada Healths AI diagnosis platform for tracking rare, immunological conditions - FierceBiotechNovartis taps Ada Health's AI diagnosis platform for tracking rare, immunological conditions - FierceBiotech
fiercebiotech.com - May 14 at 2:10 AM
Fairhaven Wealth Management, LLC Buys ARK Innovation ETF, Netflix Inc, Novartis AG, Sells First ...Fairhaven Wealth Management, LLC Buys ARK Innovation ETF, Netflix Inc, Novartis AG, Sells First ...
gurufocus.com - May 13 at 2:18 PM
Oxcarbazepine Tablets Market Share, Growth by Business Developments 2021 to 2027 – Novartis (Trileptal), Supernus Pharmaceuticals (Oxtellar XR), Apotex, Sun Pharm – The Shotcaller - The ShotcallerOxcarbazepine Tablets Market Share, Growth by Business Developments 2021 to 2027 – Novartis (Trileptal), Supernus Pharmaceuticals (Oxtellar XR), Apotex, Sun Pharm – The Shotcaller - The Shotcaller
theshotcaller.net - May 13 at 12:41 PM
Glaucoma Treatment Market Competitive Landscape Forecasts to 2027: Novartis AG, Allergan, Merck & Co., Inc., Akorn, Inc. – The Shotcaller - The ShotcallerGlaucoma Treatment Market Competitive Landscape Forecasts to 2027: Novartis AG, Allergan, Merck & Co., Inc., Akorn, Inc. – The Shotcaller - The Shotcaller
theshotcaller.net - May 13 at 7:40 AM
Global Corticosteroids Market Report 2021 Featuring Major Players - Sumitomo, Pfizer, Novartis, Merck, Sanofi, Johnson and Johnson, GSK, AstraZeneca, Cipla, and LEO Pharma - Yahoo FinanceGlobal Corticosteroids Market Report 2021 Featuring Major Players - Sumitomo, Pfizer, Novartis, Merck, Sanofi, Johnson and Johnson, GSK, AstraZeneca, Cipla, and LEO Pharma - Yahoo Finance
finance.yahoo.com - May 13 at 7:40 AM
Worldwide Multiple Myeloma Treatment Industry to 2029 - Players Include Janssen Biotech, Bristol-Myers Squibb and Novartis Among Others - Yahoo FinanceWorldwide Multiple Myeloma Treatment Industry to 2029 - Players Include Janssen Biotech, Bristol-Myers Squibb and Novartis Among Others - Yahoo Finance
finance.yahoo.com - May 13 at 7:40 AM
Ada Health partners with Novartis to work on diagnosis for immunological diseases - Mobihealth NewsAda Health partners with Novartis to work on diagnosis for immunological diseases - Mobihealth News
mobihealthnews.com - May 13 at 7:40 AM
Veterinary Ivermectin Market is set for Lucrative Growth | Top Companies – Novartis AG, Intas Pharmaceuticals. – The Manomet Current - The Manomet CurrentVeterinary Ivermectin Market is set for Lucrative Growth | Top Companies – Novartis AG, Intas Pharmaceuticals. – The Manomet Current - The Manomet Current
manometcurrent.com - May 12 at 3:51 PM
Global CAR-T Therapy Pipeline Market Analysis Report 2021-2030 Featuring Novartis, Kite Pharma, Pfizer, Juno Therapeutics, Celgene, CARsgen Therapeutics, Sorrento Therapeutics, and Legend Biotech - PRNewswireGlobal CAR-T Therapy Pipeline Market Analysis Report 2021-2030 Featuring Novartis, Kite Pharma, Pfizer, Juno Therapeutics, Celgene, CARsgen Therapeutics, Sorrento Therapeutics, and Legend Biotech - PRNewswire
prnewswire.com - May 12 at 3:51 PM
Unbossing Leaders at Novartis AG - Gallup'Unbossing' Leaders at Novartis AG - Gallup
gallup.com - May 12 at 3:51 PM
Cullen Capital Management, LLC Buys JPMorgan Chase, BCE Inc, Novartis AG, Sells General Mills ...Cullen Capital Management, LLC Buys JPMorgan Chase, BCE Inc, Novartis AG, Sells General Mills ...
gurufocus.com - May 12 at 1:43 PM
Global CAR-T Therapy Pipeline Market Analysis Report 2021-2030 Featuring Novartis, Kite Pharma, Pfizer, Juno Therapeutics, Celgene, CARsgen Therapeutics, Sorrento Therapeutics, and Legend Biotech - Yahoo FinanceGlobal CAR-T Therapy Pipeline Market Analysis Report 2021-2030 Featuring Novartis, Kite Pharma, Pfizer, Juno Therapeutics, Celgene, CARsgen Therapeutics, Sorrento Therapeutics, and Legend Biotech - Yahoo Finance
finance.yahoo.com - May 12 at 10:49 AM
LoA Update: Novartis approval likelihood for Entresto plummets by 11 points in acute myocardial - Clinical Trials ArenaLoA Update: Novartis' approval likelihood for Entresto plummets by 11 points in acute myocardial - Clinical Trials Arena
clinicaltrialsarena.com - May 12 at 10:49 AM
Organ Transplantation Market to Witness Huge Growth by 2028 | Novartis, Terumo, Roche – The Manomet Current - The Manomet CurrentOrgan Transplantation Market to Witness Huge Growth by 2028 | Novartis, Terumo, Roche – The Manomet Current - The Manomet Current
manometcurrent.com - May 11 at 5:52 PM
Rabies Vaccine for Humans Market Hissen, BCHT, Changsheng, Sanofi, Yisheng, Novartis, Prcmise, GlaxoSmithKline, Merck, Chengda, Wyeth pharmaceuticals, VACN, and More – The Manomet Current - The Manomet CurrentRabies Vaccine for Humans Market Hissen, BCHT, Changsheng, Sanofi, Yisheng, Novartis, Prcmise, GlaxoSmithKline, Merck, Chengda, Wyeth pharmaceuticals, VACN, and More – The Manomet Current - The Manomet Current
manometcurrent.com - May 11 at 5:52 PM
Carcinoid Syndrome Management Market Impressive Gains including key players Novartis, Omega Laboratories, Teva Pharmaceutical – The Manomet Current - The Manomet CurrentCarcinoid Syndrome Management Market Impressive Gains including key players Novartis, Omega Laboratories, Teva Pharmaceutical – The Manomet Current - The Manomet Current
manometcurrent.com - May 11 at 5:52 PM
Novartis (NYSE:NVS) Rating Reiterated by Morgan StanleyNovartis (NYSE:NVS) Rating Reiterated by Morgan Stanley
americanbankingnews.com - May 11 at 5:02 PM
Europe Intraocular Lens Market 2021 Precise Outlook – Novartis AG (Alcon), Bausch Health Companies Inc. (Bausch + Lomb), Carl Zeiss Meditec AG, EyeKon Medical Inc., Hoya Corporation, HumanOptics AG – The Shotcaller - The ShotcallerEurope Intraocular Lens Market 2021 Precise Outlook – Novartis AG (Alcon), Bausch Health Companies Inc. (Bausch + Lomb), Carl Zeiss Meditec AG, EyeKon Medical Inc., Hoya Corporation, HumanOptics AG – The Shotcaller - The Shotcaller
theshotcaller.net - May 11 at 12:43 PM
Precision Medicine Market SWOT Analysis by Key Players- Pfizer, Novartis, Teva – The Shotcaller - The ShotcallerPrecision Medicine Market SWOT Analysis by Key Players- Pfizer, Novartis, Teva – The Shotcaller - The Shotcaller
theshotcaller.net - May 11 at 7:43 AM
Parkinsons disease Drug Market Is Booming Worldwide | Teva, Novartis AG, GSK, AbbVie, Merck, Boehringer Ingelheim, Impax Laboratories – The Manomet Current - The Manomet CurrentParkinsons disease Drug Market Is Booming Worldwide | Teva, Novartis AG, GSK, AbbVie, Merck, Boehringer Ingelheim, Impax Laboratories – The Manomet Current - The Manomet Current
manometcurrent.com - May 11 at 7:43 AM
Megestrol Market Analysis and Research Report 2021 to 2026| Novartis, Mylan, Mayne Pharma Inc, GSK, Pfizer, Gerui Pharmaceutical Company – The Shotcaller - The ShotcallerMegestrol Market Analysis and Research Report 2021 to 2026| Novartis, Mylan, Mayne Pharma Inc, GSK, Pfizer, Gerui Pharmaceutical Company – The Shotcaller - The Shotcaller
theshotcaller.net - May 11 at 7:43 AM
Global Multiple Sclerosis Therapeutics Market Report 2021 Featuring AbbVie, Bayer, Biogen, Merck & Co, Novartis , Pfizer, Sanofi, & Teva Pharma - Market to Reach $22.3 Billion by 2027 - ResearchAndMarkets.com - Business WireGlobal Multiple Sclerosis Therapeutics Market Report 2021 Featuring AbbVie, Bayer, Biogen, Merck & Co, Novartis , Pfizer, Sanofi, & Teva Pharma - Market to Reach $22.3 Billion by 2027 - ResearchAndMarkets.com - Business Wire
businesswire.com - May 11 at 7:43 AM
Antibodies Market is set to Experience a Revolutionary growth by 2026-Novartis, F. Hoffmann-La Roche, Johnson & Johnson Services, Amgen – The Shotcaller - The ShotcallerAntibodies Market is set to Experience a Revolutionary growth by 2026-Novartis, F. Hoffmann-La Roche, Johnson & Johnson Services, Amgen – The Shotcaller - The Shotcaller
theshotcaller.net - May 10 at 4:21 PM
DateCompanyBrokerageAction
1/27/2021Johnson & JohnsonJPMorgan Chase & Co.Boost Price Target
1/27/2021Johnson & JohnsonCredit Suisse GroupBoost Price Target
1/27/2021Johnson & JohnsonRaymond JamesBoost Price Target
1/27/2021Johnson & JohnsonCowenBoost Price Target
1/27/2021Johnson & JohnsonMorgan StanleyBoost Price Target
1/27/2021Johnson & JohnsonSVB LeerinkBoost Price Target
1/27/2021Johnson & JohnsonWells Fargo & CompanyBoost Price Target
1/26/2021Johnson & JohnsonCantor FitzgeraldBoost Price Target
8/19/2020Johnson & JohnsonStifel NicolausDowngrade
7/20/2020Johnson & JohnsonBank of AmericaReiterated Rating
7/20/2020Johnson & JohnsonIndependent ResearchUpgrade
7/17/2020Johnson & JohnsonCitigroupBoost Price Target
4/29/2020Johnson & JohnsonBarclaysBoost Price Target
3/16/2021RocheJefferies Financial GroupDowngrade
3/5/2021RocheErste GroupDowngrade
2/25/2021RocheBerenberg BankReiterated Rating
2/17/2021RocheUBS GroupDowngrade
2/4/2021RocheOddo BhfDowngrade
1/15/2021RocheDeutsche Bank AktiengesellschaftInitiated Coverage
9/28/2020RocheSociete GeneraleReiterated Rating
7/13/2020RocheSanford C. BernsteinInitiated Coverage
7/3/2020RocheAlphaValueUpgrade
5/13/2020RocheWolfe ResearchUpgrade
4/30/2020RocheHSBCUpgrade
4/21/2021Abbott LaboratoriesAtlantic SecuritiesInitiated Coverage
4/20/2021Abbott LaboratoriesWilliam BlairReiterated Rating
1/28/2021Abbott LaboratoriesBTIG ResearchUpgrade
9/2/2020Abbott LaboratoriesThe Goldman Sachs GroupSet Price Target
5/12/2021PfizerMizuhoReiterated Rating
4/7/2021PfizerRoyal Bank of CanadaInitiated Coverage
2/3/2021PfizerDZ BankReiterated Rating
3/16/2021NovartisArgusReiterated Rating
(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.